Züri Can 研究：规范大麻销售能否促进低风险大麻使用？小综述和研究方案

IF 4.4 2区医学 Q1 SUBSTANCE ABUSE

International Journal of Drug Policy Pub Date : 2024-10-11 DOI:10.1016/j.drugpo.2024.104610

Maximilian Buschner, Nadine Heckel, Patricia Dürler, Etna J․ E. Engeli, Sophie Schneider, Eva M. Havelka, Carlos Nordt, Marcus Herdener

{"title":"Züri Can 研究：规范大麻销售能否促进低风险大麻使用？小综述和研究方案","authors":"Maximilian Buschner, Nadine Heckel, Patricia Dürler, Etna J․ E. Engeli, Sophie Schneider, Eva M. Havelka, Carlos Nordt, Marcus Herdener","doi":"10.1016/j.drugpo.2024.104610","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and Aims</h3><div>Recreational use of cannabis is illegal in most countries. Despite this, it is the third most commonly used psychoactive substance worldwide. As a result of this discrepancy, a growing number of countries have begun to reassess their legal approach to cannabis in recent years. While the health risks of cannabis and potential harm reduction measures are increasingly well understood, there are still significant gaps in knowledge about which regulatory and supply models are effective in promoting lower-risk cannabis use.</div><div>In this paper, we outline the Züri Can study, which implements and evaluates a regulatory framework for cannabis sales in the city of Zurich, Switzerland, between 2023 and 2026. In addition, we illustrate how the study addresses current knowledge gaps to provide further insight into the potential future regulation of cannabis in Switzerland.</div><div>To embed the study in the present scientific and political context, we first provide a brief overview of the state of knowledge on cannabis-related health risks and means of reducing them, along with lessons learned from other countries that have implemented varying regulatory systems.</div></div><div><h3>Design and Measurements</h3><div>2,100 participants will be able to legally purchase cannabis either at a pharmacy, a cannabis social club, or the municipal drug information center over a three-year period. As part of this observational study, participants will be evaluated regarding their cannabis use habits and motives, their knowledge of lower-risk use, and their mental and physical health, among other parameters.</div><div>Established harm reduction strategies are implemented as an integral part of the study design.</div></div><div><h3>Comments</h3><div>The study will contribute to a better understanding of the impact of different cannabis distribution models on cannabis use patterns and related health outcomes. The results are expected to assist Swiss and international policy makers in developing evidence-based and public health-oriented regulatory frameworks for cannabis.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"133 ","pages":"Article 104610"},"PeriodicalIF":4.4000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Züri Can study: Can regulated cannabis sales promote lower-risk cannabis use? Mini-review and study protocol\",\"authors\":\"Maximilian Buschner, Nadine Heckel, Patricia Dürler, Etna J․ E. Engeli, Sophie Schneider, Eva M. Havelka, Carlos Nordt, Marcus Herdener\",\"doi\":\"10.1016/j.drugpo.2024.104610\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background and Aims</h3><div>Recreational use of cannabis is illegal in most countries. Despite this, it is the third most commonly used psychoactive substance worldwide. As a result of this discrepancy, a growing number of countries have begun to reassess their legal approach to cannabis in recent years. While the health risks of cannabis and potential harm reduction measures are increasingly well understood, there are still significant gaps in knowledge about which regulatory and supply models are effective in promoting lower-risk cannabis use.</div><div>In this paper, we outline the Züri Can study, which implements and evaluates a regulatory framework for cannabis sales in the city of Zurich, Switzerland, between 2023 and 2026. In addition, we illustrate how the study addresses current knowledge gaps to provide further insight into the potential future regulation of cannabis in Switzerland.</div><div>To embed the study in the present scientific and political context, we first provide a brief overview of the state of knowledge on cannabis-related health risks and means of reducing them, along with lessons learned from other countries that have implemented varying regulatory systems.</div></div><div><h3>Design and Measurements</h3><div>2,100 participants will be able to legally purchase cannabis either at a pharmacy, a cannabis social club, or the municipal drug information center over a three-year period. As part of this observational study, participants will be evaluated regarding their cannabis use habits and motives, their knowledge of lower-risk use, and their mental and physical health, among other parameters.</div><div>Established harm reduction strategies are implemented as an integral part of the study design.</div></div><div><h3>Comments</h3><div>The study will contribute to a better understanding of the impact of different cannabis distribution models on cannabis use patterns and related health outcomes. The results are expected to assist Swiss and international policy makers in developing evidence-based and public health-oriented regulatory frameworks for cannabis.</div></div>\",\"PeriodicalId\":48364,\"journal\":{\"name\":\"International Journal of Drug Policy\",\"volume\":\"133 \",\"pages\":\"Article 104610\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2024-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Drug Policy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0955395924002949\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"SUBSTANCE ABUSE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Drug Policy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0955395924002949","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}

引用次数: 0

摘要

背景和目的在大多数国家，娱乐性使用大麻是非法的。尽管如此，大麻却是全球第三大最常用的精神活性物质。由于这种差异，近年来越来越多的国家开始重新评估其对大麻的法律态度。虽然人们对大麻的健康风险和潜在的减害措施有了越来越深入的了解，但在哪些监管和供应模式能有效促进低风险大麻使用方面仍存在巨大的知识差距。在本文中，我们概述了 Züri Can 研究，该研究实施并评估了 2023 年至 2026 年期间瑞士苏黎世市的大麻销售监管框架。此外，我们还说明了该研究如何解决当前的知识缺口，从而为瑞士未来可能的大麻监管提供更深入的见解。为了将该研究纳入当前的科学和政治背景，我们首先简要概述了与大麻相关的健康风险和降低风险的方法的知识状况，以及从其他实施了不同监管制度的国家吸取的经验教训。设计和测量2,100 名参与者将能够在三年内通过药店、大麻社交俱乐部或市级毒品信息中心合法购买大麻。作为这项观察性研究的一部分，将对参与者的大麻使用习惯和动机、对低风险使用的了解以及他们的身心健康等参数进行评估。这项研究将有助于更好地了解不同大麻销售模式对大麻使用模式和相关健康结果的影响。预计研究结果将有助于瑞士和国际政策制定者制定以证据为基础、以公共健康为导向的大麻监管框架。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Züri Can study: Can regulated cannabis sales promote lower-risk cannabis use? Mini-review and study protocol

Background and Aims

Recreational use of cannabis is illegal in most countries. Despite this, it is the third most commonly used psychoactive substance worldwide. As a result of this discrepancy, a growing number of countries have begun to reassess their legal approach to cannabis in recent years. While the health risks of cannabis and potential harm reduction measures are increasingly well understood, there are still significant gaps in knowledge about which regulatory and supply models are effective in promoting lower-risk cannabis use.

In this paper, we outline the Züri Can study, which implements and evaluates a regulatory framework for cannabis sales in the city of Zurich, Switzerland, between 2023 and 2026. In addition, we illustrate how the study addresses current knowledge gaps to provide further insight into the potential future regulation of cannabis in Switzerland.

To embed the study in the present scientific and political context, we first provide a brief overview of the state of knowledge on cannabis-related health risks and means of reducing them, along with lessons learned from other countries that have implemented varying regulatory systems.

Design and Measurements

2,100 participants will be able to legally purchase cannabis either at a pharmacy, a cannabis social club, or the municipal drug information center over a three-year period. As part of this observational study, participants will be evaluated regarding their cannabis use habits and motives, their knowledge of lower-risk use, and their mental and physical health, among other parameters.

Established harm reduction strategies are implemented as an integral part of the study design.

Comments

The study will contribute to a better understanding of the impact of different cannabis distribution models on cannabis use patterns and related health outcomes. The results are expected to assist Swiss and international policy makers in developing evidence-based and public health-oriented regulatory frameworks for cannabis.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Drug Policy SUBSTANCE ABUSE-

CiteScore

7.80

自引率

11.40%

发文量

307

审稿时长

62 days

期刊介绍： The International Journal of Drug Policy provides a forum for the dissemination of current research, reviews, debate, and critical analysis on drug use and drug policy in a global context. It seeks to publish material on the social, political, legal, and health contexts of psychoactive substance use, both licit and illicit. The journal is particularly concerned to explore the effects of drug policy and practice on drug-using behaviour and its health and social consequences. It is the policy of the journal to represent a wide range of material on drug-related matters from around the world.